CEFOTAN (cefotetan) by R-Pharm US is clinical pharmacology high plasma levels of cefotetan are attained after intravenous and intramuscular administration of single doses to normal volunteers. First approved in 1985.
Drug data last refreshed 45m ago · AI intelligence enriched 1w ago
Cefotetan is a second-generation cephalosporin antibiotic administered via intravenous or intramuscular injection. It works by inhibiting bacterial cell wall synthesis and demonstrates bactericidal activity against a broad spectrum of pathogens, including some beta-lactamase-producing organisms. The drug achieves therapeutic concentrations across multiple body tissues and fluids, making it suitable for serious infections in various anatomical sites.
As an older injectable antibiotic approaching loss of exclusivity with moderate competitive pressure (30/100), the brand team is likely contracting and focused on cost management and retention in hospital formularies rather than growth initiatives.
CLINICAL PHARMACOLOGY High plasma levels of cefotetan are attained after intravenous and intramuscular administration of single doses to normal volunteers. PLASMA CONCENTRATIONS AFTER 1 GRAM IV OR IM DOSE Mean Plasma Concentration (mcg/mL) Time After Injection Route 15 min 30 min 1 h 2 h 4 h 8 h 12…
Worked on CEFOTAN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Cefotetan Therapy for Escherichia Coli Infections
Working on cefotetan offers limited career growth due to its LOE-approaching status and mature market; roles are primarily defensive and focused on maintaining market share in hospital systems rather than driving innovation or expansion. Professionals on this team should expect a smaller organization with emphasis on cost management, formulary retention, and operational efficiency rather than revenue growth.